Region:Asia
Author(s):Shubham
Product Code:KRAC8942
Pages:90
Published On:November 2025

By Technology:The technology segment includes various genome editing methods that are pivotal in the market. The leading technologies areCRISPR/Cas systems, TALENs, ZFNs, base editors, and other genome editing technologies. CRISPR/Cas systems dominate due to their versatility, efficiency, and cost-effectiveness, making them the preferred choice for researchers and companies alike. The adoption of precision editors and improved delivery vectors is further accelerating the use of CRISPR-based technologies in both research and commercial applications .

By Application:The application segment encompasses various fields where genome editing technologies are utilized. The primary applications includeagriculture, human therapeutics, industrial biotechnology, and research tools. Agriculture is the leading application area, driven by the need for crop improvement, disease resistance, and enhanced livestock genetics, which are crucial for food security and sustainability. Human therapeutics is rapidly expanding, supported by the development of gene therapies and personalized medicine approaches .

The Vietnam Genome Editing Market is characterized by a dynamic mix of regional and international players. Leading participants such as VinBioCare, Genetica, Vingroup, Hanoi Medical University, Institute of Biotechnology (Vietnam Academy of Science and Technology), Vietnam National University, Hanoi, FPT Digital Healthcare, Ho Chi Minh City University of Science (Vietnam National University, Ho Chi Minh City), Biomedic, AgriGenome Vietnam, Vietnam Academy of Science and Technology, Southern Institute of Ecology, Vietnam National University of Agriculture, Hanoi University of Science and Technology, and National Institute of Plant Protection contribute to innovation, geographic expansion, and service delivery in this space .
The future of the Vietnam genome editing market appears promising, driven by technological advancements and increasing agricultural demands. As the government continues to invest in biotechnology and streamline regulatory processes, the market is expected to witness accelerated growth. Additionally, the integration of AI in genome editing and a growing focus on sustainable agricultural practices will likely enhance productivity and efficiency. These trends indicate a robust environment for innovation and collaboration within the sector, positioning Vietnam as a key player in the biotechnology landscape.
| Segment | Sub-Segments |
|---|---|
| By Technology | CRISPR/Cas Systems TALENs (Transcription Activator-Like Effector Nucleases) ZFNs (Zinc Finger Nucleases) Base Editors & Prime Editors Other Genome Editing Technologies |
| By Application | Agriculture (Crop Improvement, Disease Resistance, Livestock Genetics) Human Therapeutics (Gene Therapy, Rare Diseases, Oncology) Industrial Biotechnology (Biomanufacturing, Synthetic Biology) Research Tools & Diagnostics |
| By End-User | Academic & Research Institutes Biotechnology & Pharmaceutical Companies Government & Regulatory Bodies Contract Research Organizations (CROs) Others |
| By Funding Source | Government Grants Private Investments Venture Capital International Collaborations Others |
| By Region | Northern Vietnam Central Vietnam Southern Vietnam Others |
| By Policy Support | Subsidies Tax Incentives Research Grants Regulatory Fast-Track Programs Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Agricultural Biotechnology Firms | 60 | CEOs, R&D Directors, Agronomists |
| Healthcare and Pharmaceutical Companies | 50 | Clinical Researchers, Product Managers, Regulatory Affairs Specialists |
| Academic and Research Institutions | 40 | Professors, Research Scientists, Graduate Students |
| Government Regulatory Bodies | 40 | Policy Makers, Regulatory Analysts, Biotechnology Advisors |
| Biotechnology Investment Firms | 40 | Investment Analysts, Portfolio Managers, Venture Capitalists |
The Vietnam Genome Editing Market is valued at approximately USD 2.3 billion, reflecting significant growth driven by advancements in biotechnology, increased R&D investments, and rising demand for genetically modified crops and therapies.